Epizyme Partner Spotlight
Dr Jennifer Gao and colleagues found the addition of CDK4/6 inhibitor treatment to fulvestrant resulted in a consistent OS benefit vs placebo plus fulvestrant in patients with HR+...
Study authors characterized the adaptive roles of PI3Kα mutations among HER2+ tumor progression.
Dr John P. Leonard discusses the complex landscape and management of patients with lymphoma, as well as hot topics in hematologic malignancies, including the use of monsunetuzumab therapy.
A phase III trial found that the addition of the AKT inhibitor ipatasertib to abiraterone and prednisolone produced a significant improvement in radiographic progression-free survival...
This research works to advance the ability to create individualized therapy regimens and guide SCLC prognostication.
This study works to determine the demographic, histopathologic and clinical characteristics of cancer patients most impacted by COVID-19.